Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 16/20 | 0.35 |
| ▸ | CNR2 | P34972 | 16/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.35 |
| ▸ | TLR3 | O15455 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16335108 | 0.82 | TDP1 (0.40) | — | |
| SCHEMBL16335364 | 0.82 | KDM4E (0.40) | — | |
| SCHEMBL16335071 | 0.78 | IL2 (0.46) | — | |
| SCHEMBL19227409 | 0.75 | STIM1 (0.35) | — | |
| SCHEMBL16334460 | 0.73 | TDP1 (0.42) | RAF1 | |
| SCHEMBL16334785 | 0.73 | KDM4E (0.41) | KCNH2RAF1 | |
| SCHEMBL16362060 | 0.73 | PTGER3 (0.40) | TRPV1 | |
| SCHEMBL16362104 | 0.71 | PTGER3 (0.40) | TRPV1 | |
| SCHEMBL17766361 | 0.70 | CYP11B2 (0.39) | — | |
| SCHEMBL17766354 | 0.70 | CYP11B2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790231-B2 | Chromane and chromene derivatives and their use as CRAC modulators | LUPIN LIMITED (IN) | 2017-10-17 | — | — | US | disclosed |
| US-20160137659-A1 | CHROMANE AND CHROMENE DERIVATIVES AND THEIR USE AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-19 | — | — | US | disclosed |
| WO-2014207648-A1 | CHROMANE AND CHROMENE DERIVATIVES AND THEIR USE AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137659-A1 | CHROMANE AND CHROMENE DERIVATIVES AND THEIR USE AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | CNR1 121/4885CNR2 118/4885KCNH2 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.